Nature Communication publishes application of switchSENSE technology in multivalent antibody development
Leiden, July 18, 2021 – Today, Andreas Plückthun’s group at the University of Zurich publishes on Nature Communication with the help of switchSENSE technology. The paper shows that an engineered anti-Her2 tetravalent antibody construct that…
UK eases the way to market for biosimilars
Today, UK’s Medicines & Healthcare products Regulatory Agency (MHRA) published the final guidance on the licensing of biosimilar products, lowering the barrier for biosimilar drug to enter the market. Today’s final version follows draft guidelines…
Conformation analysis realized by switchSENSE published in Proceedings of National Academy of Science
La Jolla, LA, March 30, 2021 – Litao Sun, et al, at Scripps Research used the switchSENSE® technology in their paper to analyze the different conformations of the wild-type and mutant versions of the alanyl-tRNA…
Mimetas teams up with pharma and academia to develop renal tubule-on-a-chip for nephrotoxicity assessment
Leiden, March 22, 2021 – Scientists from MIMETAS, Roche Innovation Center, Pfizer, GlaxoSmithKline (GSK), Utrecht Institute for Pharmaceutical Sciences, University of Applied Sciences Northwestern Switzerland, and the Swiss Centre for Applied Human Toxicology, developed a…
MIMETAS Opens Phenotypic Screening Center for large-scale drug candidate screnning campaigns on Organ-on-a-Chip models
LEIDEN, May 27, 2021 – MIMETAS, the global leader in human-relevant organ-on-a-chip models, has just opened their Phenotypic Screening Center. The center facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the…
BiosanaPharma announces successful phase I of omalizumab biosimilar
Sydney/Leiden, March 30, 2020 (updated November 2021) – BiosanaPharma, an Australian/Dutch biotech company, today announced the successful outcome of a comparative phase I clinical study in healthy volunteers of BP001, a biosimilar candidate to Xolair®….
MIMETAS and Hubrecht Organoid Technologies to Develop and Market Organoids-on-a-Chip
LEIDEN & UTRECHT, October 01 , 2019 – MIMETAS and Hubrecht Organoid Technologies (HUB) announce that they entered into a strategic collaboration to market organoid models on a Chip. The agreement includes a license to…
Mimetas lands $21m for organ-on-a-chip tech
LEIDEN, April 11, 2018 – Mimetas said today that it raised $20.5 million in a Series B round from a syndicate of investors in Asia and Europe. The Netherlands-based company intends to use its newly-acquired…
- « Previous
- 1
- 2